Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* HCV RNA ≥ 10\^4 IU/mL at screening~* Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy~Key Exclusion Criteria:~* Any other chronic liver disease~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Clinical hepatic decompensation~* Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A inhibitor~Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).